Trevogrumab  (Synonyms: REGN-1033)

Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as myostatin). Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

Trevogrumab (40 nM, 30 minutes) demonstrates strong inhibition of myostatin in human skeletal myoblasts^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Trevogrumab (10 mg/kg, s.c., twice a week for 4 weeks) significantly increases muscle mass and strength in CB17-SCID and C57BL/6 mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1429201-24-0

Liquid

Colorless to light yellow

[Trevogrumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized GDF-8 Protein, Human can bind Trevogrumab. The EC₅₀ for this effect is 75 ng/mL.

• [1]. Masakazu Saitoh, et al. Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. Volume2, Issue1,January 2017,Pages 1-10

  [2]. Mitra A, et al. The elusive role of myostatin signaling for muscle regeneration and maintenance of muscle and bone homeostasis. Osteoporos Sarcopenia. 2023 Mar;9(1):1-7.  [Content Brief]

  [3]. Latres E, et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle. 2015 Oct 9;5:34.  [Content Brief]